Bioorthogonal Sonodynamic Plug‐and‐Play Targeting Chimeras (SDPTAC) for Precise Targeted Protein Degradation
Source abstract
Abstract
ABSTRACT Targeted protein degradation (TPD) offers powerful therapeutic opportunities but is limited by poor tissue penetration and E3 ligase dependence. Herein, we develop Sonodynamic Plug‐and‐Play Targeting Chimeras (SDPTAC), an ultrasound (US)‐activated, bioorthogonal strategy for in situ protein degradation. SDPTAC assembles via an inverse electron‐demand Diels–Alder (IEDDA) click reaction between a sonosensitizer and tetrazine‐tagged ligands, generating reactive oxygen species (ROS) upon US to degrade bound proteins. This modular platform enabled efficient degradation of nuclear (bromodomain‐containing protein 4, BRD4), cytosolic (nicotinamide phosphoribosyl transferase, NAMPT), and membrane (discoidin domain receptor 1, DDR1) targets, suppressed oncogenic signaling, and achieved nearly complete tumor growth inhibition in vivo with negligible toxicity. SDPTAC thus establishes a versatile, deep‐penetrating, and clinically translatable approach for noninvasive protein modulation.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Click Chemistry and Applications · Protein Degradation and Inhibitors · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Institute of Translational Medicine or School of Medicine Shanghai University Shanghai P. R. China
Department The Center for Basic Research and Innovation of Medicine and Pharmacy (MOE) School of Pharmacy Second Military Medical University (Naval Medical University) Shanghai P. R. China
Funding
National Natural Science Foundation of China · National Key Research and Development Program of China · Natural Science Foundation of Fujian Province
References (32)
Show source-provided references
1. 10.1016/j.chembiol.2021.04.01110.1016/j.chembiol.2021.04.011 ↗
2. 10.1038/s41580-024-00729-910.1038/s41580-024-00729-9 ↗
3. 10.1016/j.chembiol.2020.07.02010.1016/j.chembiol.2020.07.020 ↗
4. 10.1021/acs.jmedchem.1c0089510.1021/acs.jmedchem.1c00895 ↗
5. 10.1016/j.molcel.2019.09.00910.1016/j.molcel.2019.09.009 ↗
6. 10.1038/s41467-022-28520-410.1038/s41467-022-28520-4 ↗
7. 10.1038/s41392-022-00966-410.1038/s41392-022-00966-4 ↗
8. 10.1039/D2CS00193D10.1039/D2CS00193D ↗
9. 10.1039/D2CS00200K10.1039/D2CS00200K ↗
10. 10.1039/D2CS00220E10.1039/D2CS00220E ↗
11. 10.1021/acs.jmedchem.2c0085510.1021/acs.jmedchem.2c00855 ↗
12. 10.1021/acs.jmedchem.1c0203710.1021/acs.jmedchem.1c02037 ↗
13. 10.1002/anie.20240325810.1002/anie.202403258 ↗
14. 10.1016/j.biomaterials.2025.12310110.1016/j.biomaterials.2025.123101 ↗
15. 10.1016/j.csbj.2019.11.00710.1016/j.csbj.2019.11.007 ↗
16. 10.1038/nrd166210.1038/nrd1662 ↗
17. 10.1016/j.nantod.2020.10094910.1016/j.nantod.2020.100949 ↗
18. 10.1039/C9CS00648F10.1039/C9CS00648F ↗
19. 10.1016/j.canlet.2022.21559210.1016/j.canlet.2022.215592 ↗
20. 10.1021/acs.molpharmaceut.4c0135910.1021/acs.molpharmaceut.4c01359 ↗
21. 10.1007/s41061-023-00446-510.1007/s41061-023-00446-5 ↗
22. 10.1021/acs.jmedchem.3c0145910.1021/acs.jmedchem.3c01459 ↗
23. 10.1002/anie.20090094210.1002/anie.200900942 ↗
24. 10.1021/acs.accounts.5c0000310.1021/acs.accounts.5c00003 ↗
25. 10.1002/anie.20210734710.1002/anie.202107347 ↗
26. 10.1021/acs.jmedchem.3c0153910.1021/acs.jmedchem.3c01539 ↗
27. 10.1002/anie.20231599710.1002/anie.202315997 ↗
28. 10.1021/acs.orglett.2c0101010.1021/acs.orglett.2c01010 ↗
29. 10.1038/nature0950410.1038/nature09504 ↗
30. 10.1038/nchembio.232910.1038/nchembio.2329 ↗
31. 10.1038/nrendo.2015.11710.1038/nrendo.2015.117 ↗
32. 10.1007/s10555-012-9346-z10.1007/s10555-012-9346-z ↗